Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Sep
06
Today In Oncology
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo